Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Share-based Compensation (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Share-based Compensation data on record, last reported at $19.0 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 43.58% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $71.4 million, up 47.44%, while the annual FY2025 figure was $71.4 million, 47.44% up from the prior year.
  • Share-based Compensation reached $19.0 million in Q4 2025 per MIRM's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $19.0 million in Q4 2025 and bottomed at $4.8 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $10.2 million, with a median of $8.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 116.31% in 2021, then fell 6.84% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $5.6 million in 2021, then rose by 23.94% to $6.9 million in 2022, then skyrocketed by 40.95% to $9.7 million in 2023, then skyrocketed by 36.33% to $13.3 million in 2024, then surged by 43.58% to $19.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $19.0 million in Q4 2025, $18.1 million in Q3 2025, and $18.5 million in Q2 2025.